News Release
April 7, 2020
MilliporeSigma Awarded Second U.S. Patent for CRISPR Gene-Editing Technology
- CRISPR-chrom technology improves access to genome for more efficient editing
- Only U.S. patent holder in the CRISPR chromatin space
- MilliporeSigma driving innovation in CRISPR gene-editing technologies
Burlington, Massachusetts, April 7, 2020— MilliporeSigma, a leader in genome editing, today announced that the United States Patent and Trademark Office has granted the company’s patent for CRISPR-chrom technology. With this allowance, MilliporeSigma is the only provider with a patent covering the fusion of chromatin modulating peptides to CRISPR proteins, helping to clear chromatin out of the way, increasing access to the genome.
“This award marks our second U.S. CRISPR patent and our 23rd CRISPR-related patent worldwide, and as a leading innovator of CRISPR technology, we will continue to drive innovation and collaborate with scientists around the world to ensure they have the most advanced gene-editing options,” said Udit Batra, CEO, MilliporeSigma.
Because genomic DNA in mammalian cells is wrapped tightly in protein complexes called chromatin, the genomic DNA is often inaccessible to CRISPR. MilliporeSigma’s CRISPR-chrom technology works by fusing chromatin modulating peptides to a CRISPR protein, Cas9 (i.e., CRISPR’s DNA scissors), allowing for more efficient gene editing. This work was initially published in the February 2018 issue of The CRISPR Journal and was one of the journal’s top five downloaded articles of the year.
MilliporeSigma conducts research and development to drive improvements in gene-editing technologies.
The company’s CRISPR patent portfolio includes patents for CRISPR-related technologies covering foundational and alternative genome-editing methods. Patents for its CRISPR integration technology have been granted in Australia, Canada, China, Europe, Israel, Singapore and South Korea. Patents granted in Europe and pending elsewhere cover plasmid or viral vectors encoding CRISPR systems, which are necessary to perform genome modification in eukaryotic cells. Other European patents and pending applications are for protein-RNA nickase compositions.
MilliporeSigma received its first U.S. patent in February 2019 for its proxy-CRISPR technology, which makes CRISPR more efficient, flexible and specific. The company has successfully out-licensed its CRISPR patent portfolio and continues to license its entire CRISPR patent portfolio for all fields of use. MilliporeSigma is proactively and aggressively pursuing CRISPR patent out-licensing partners for therapeutics, agriculture and research and welcomes such collaboration opportunities.
CRISPR technology is a core competency for MilliporeSigma, which has 16 years’ experience with genome editing, spanning from discovery to manufacturing. The company develops technologies in a range of genome-editing applications, including gene knockout, gene integration and CRISPR libraries for genetic screens, among others.
The company recognizes that genome editing has resulted in major advancements in biological research and medicine. At the same time, the growing potential of genome-editing technologies has opened scientific, legal and societal concerns. The company supports research with genome editing under careful consideration of ethical and legal standards. MilliporeSigma’s parent company, Merck KGaA, Darmstadt, Germany, has established an independent, external Bioethics Advisory Panel to provide guidance for research in which its businesses are involved, including research on or using genome editing, and has developed, defined and transparently published a clear operational position taking into account scientific and societal issues to inform promising therapeutic approaches for use in research and applications.
Follow MilliporeSigma on Twitter @MilliporeSigma, on Facebook @MilliporeSigma and on LinkedIn.
About the Life Science Business of Merck KGaA, Darmstadt, Germany
The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has some 22,000 employees and 59 manufacturing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing, and testing services.
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science, and electronics. Around 58,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2020, Merck KGaA, Darmstadt, Germany generated sales of € 17.5 billion in 66 countries.
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck, KGaA, Darmstadt, Germany, visit www.emdgroup.com.